Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses

[cafead]

via Immunovant has reported positive results from a trial investigating its monoclonal antibody drug batoclimab in Graves’ disease patients, as its other autoimmune candidate IMVT-1402 inches closer to a pivotal trial later this year.

article source